Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Nat Rev Drug Discov. 2022 Feb 1;21(4):261–282. doi: 10.1038/s41573-021-00387-y

Figure 6. Discovery of tumour rejection antigens.

Figure 6

As the term “tumour rejection“ and the conditions under which to assess it are not standardised, experimental mouse model setups are used that differ conceptually and provide answers to different questions. These include tumour challenge of naive mice83,84 as well as of tumour- or vaccine-experienced mice258,259 and assessment of rejection spontaneously83,84 or upon various modalities of immunotherapy6,23,53,102.